The human microbiome market is expected to reach US$ 1,873.53 million in 2027 from US$ 356.29 million in 2019. The market is estimated to grow at a CAGR of 23.6% from 2020 to 2027.
The human microbiome market is expected to reach US$ 1,873.53 million in 2027 from US$ 356.29 million in 2019. The market is estimated to grow at a CAGR of 23.6% from 2020 to 2027.
The growth of the market is driven by the factors, such as increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However, strict government guidelines and the lack of knowledge and detailed examination are likely to have a negative impact on the growth of the market in the coming years.
Based on product, the human microbiome market is segmented into probiotics, foods, prebiotics, medical foods, diagnostic devices, drugs, and supplements. In 2019, the probiotics segment held the largest share of the human microbiome market. This segment is expected to dominate the market in 2027 owing to increasing health concerns; growing awareness regarding the relation of nutrition, diet, and health; and increasing probiotics market penetration in dairy and other foods. Furthermore, the prebiotics segment is anticipated to witness the fastest growth rate during the forecast period.
Request for Sample of Human Microbiome Market to know which pharma-biotech company is expected to be at the forefront in the coming years @ https://www.theinsightpartners.com/sample/TIPBT00002233/
Some of the Prominent/Emerging Players in Human Microbiome Market:
Enterome; Rebiotix Inc.; Yakult Honsha Co., Ltd.; Osel Inc.; Vedanta Biosciences, Inc.; Synthetic Biologics, Inc.; DuPont; BiomX Ltd; MaaT Pharma; Eligo Bioscience; Merck & Co., Inc.; AOBiome LLC; Kaleido; and Seres Therapeutics are among the leading companies operating in the human microbiome market.
Key Questions regarding Current Human Microbiome Market Landscape
- What are the current options for Human Microbiome Market?
- How many companies are developing for the Human Microbiome Market?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Human Microbiome market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current Human Microbiome Market?
- What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Human Microbiome?
- What are the critical designations that have been granted for Human Microbiome Market?
Several players have observed good demand for human microbiome based products during the initial period of COVID-19, particularly from the food & beverages industry. In addition, researchers are studying the correlation between gut bacteria and COVID-19. Many researchers have showcased gut bacteria’s implication in different health conditions, from type 2 diabetes to depression. However, the obstacles in supply chains and distribution networks resulting in unavailability of human microbiome based products in various parts of the world are likely to hamper the growth of the market in 2020.
Fecal microbiota transplantation (FMT) has emerged as an effective treatment for C. difficile infection (CDI). The microbiota have important roles in the function of gastrointestinal tract and other aspects of human physiology. There has been rise in interest in studying FMT for other clinical indications. The US Food and Drug Administration (FDA) has classified human stool as a biological agent and determined that the use of human stool in FMT therapy and other research must be regulated for the insurance of patient safety. To use FMT in the treatment of recurrent Clostridium difficile infection, an investigational new drug permit is not required, but it is strongly encouraged and may ultimately be required.
In March 2016, the US FDA released clarifying guidance and the draft of Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements that focused on the use of Fecal Microbiota for Transplantation to Treat Clostridium difficile infection when the patients is not responsive to standard therapies. Some of the available data suggests that the use of fecal microbiota for the restoration of intestinal flora may be an effective therapy in the management of refractory C. difficile infection. However, the efficiency and protection profiles of this intervention have not yet been fully evaluated in controlled clinical trials. Thus, the investigational drug requirement plays a vital role in the application of microbiome, thereby giving it an array of opportunities in future.
Human Microbiome Market – by Product
- Probiotics
- Foods
- Prebiotics
- Medical Foods
- Diagnostic Device
- Drugs
- Supplements
Human Microbiome Market – by Disease
- Obesity
- Diabetes
- Autoimmune Disorders
- Cancer
- Mental Disorders
- Others
Human Microbiome Market – by Application
- Therapeutics
- Diagnostics
Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPBT00002233/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense, Food & beverage, Chemical and Materials, Semiconductors. Etc.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com